Sun Pharmaceutical Industries Limited (SUNPHARMA) — Corporate Action Announcement
📢 Key Event
Sun Pharma declares final dividend of Rs 5 per share for FY26, totaling Rs 16 including interim, after board approval of audited results.
🔄 What Changed
Final dividend increased to Rs 5 per share; tax rate reduced to 25.168% with Rs 1,030 million tax credit recognized; Organon acquisition progress confirmed.
🔮 What's Next
Organon acquisition expected to close by Q3 2026; new tax regime effective from FY27; R&D investment to remain at 6.7% of sales in Q4FY26.
💡 Investor Takeaway
The dividend increase and tax benefits enhance shareholder returns, while the Organon deal and tax optimization improve long-term earnings visibility.
Sun Pharmaceutical announced a final dividend of Rs 5 per share for FY26, totaling Rs 16 per share including interim, following approval of audited financial results and an unmodified auditor's opinion. The company reported consolidated revenue of [amount context mismatch] bn with 11.9% growth and a 30.3% EBITDA margin, while finalizing the $11.75bn Organon acquisition and adopting a new 25.168% tax regime resulting in a Rs 1,030 million tax credit.
📄 View Original Announcement (PDF)
About Sun Pharmaceutical Industries Limited (SUNPHARMA)
Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE
Market Cap: ₹4,50,643.09 Cr
P/E: 41.3
ROE: 15.1%
ROCE: 20.3%
Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.